Edited by Duncan Matthews, Professor of Intellectual Property Law, Queen Mary University of London, UK and Herbert Zech, Humboldt University, Berlin, Germany

• Contents:PrefacePart I - Medicine and Pharmaceutics1. Patenting BiosimilarsClaudia Mund 2. Patenting DiagnosticsDieter Wächter 3. Patenting Human Genes in Europe- And how it compares to the US and AustraliaTimo Minssen4. Patenting Human Genes in the United StatesSamantak Gosh5. An Exorbitant Monopoly: The High Court of Australia, Myriad Genetics, and Gene PatentsMatthew Rimmer6. Exclusivity for BiologicsDuncan Matthews Part II - Agricultural Sector (Crop Sciences)7. Protection of Plant InnovationsGert Würtenberger8. Patenting Non Transgenic Plants in the EUMichael A. Kock9. Non-Obvious PlantsMark D. Janis 10. Transgenic PlantsJames Allred11. Convention on Biological Diversity and Regulatory Law as Plant ProtectionClaudio Chiarolla 12. Patents on Native Traits: What Scope of Protection?Axel Metzger Part III - Research and Development13. The European Union’s IP Policy and Funding of Stem Cell Research Aurora Plomer 14. Stem Cell Patents in the United StatesJohn M. Golden 15. Early Stage Patenting, the US Bayh-Dole Act, and the Anti-Commons HypothesisCharles R. McManis and Brian Yagi16. IP in Research and Development AgreementsMelanie Graf and Herbert Zech 17. Patent pools and clearinghouses in the life sciences: back to the futureGeertrui Van OverwallePart IV - Country Case Studies in IP and the Life Sciences18. Understanding the Brazilian Patent ReformPedro Paranaguá19. IP protection in the life sciences in ChinaLin Xiuqin and Zhang Xinfeng20. Diverse Harmonization: Indian ExampleSrividhya Ragavan 21. Life Science Research and Patents in Japan: A Comparative Study of Life Science Invention Patentability between the Japanese and US Patent ActsToshiko Takenaka 22. Intellectual Property and the Life Sciences in Kenya: Enforcement and Access to MedicinesJohn Harrington 23. IP and Life Sciences: A Case Study of South AfricaTenu Avafia 24. Thailand’s Compulsory Licenses and the Increase of Investment ArbitrationDavid B. DegenPart V - Boundaries of IP and the Life Sciences25. Parallel Imports within the European UnionGert Würtenberger26. Pay for Delay AgreementsClaudia Seitz 27. Abusive Filing of IP RightsAndreas HeinemannIndex

'This exciting volume offers fresh perspectives on the role of IP in areas of high importance, including traditional pharmaceutical industries, biologic drugs and biotechnology, and agriculture. The book also features analyses of IP in national and regional approaches to research and development, and fresh case studies of country experiences. With the participation of authors from a wide range of countries, the volume provides new insights on the law and politics of IP in the life sciences with a truly global perspective. This book will serve as a valuable reference for scholars, students, and practioners.'

Edited by Duncan Matthews, Professor of Intellectual Property Law, Queen Mary University of London, UK and Herbert Zech, Humboldt University, Berlin, Germany

• Contents:PrefacePart I - Medicine and Pharmaceutics1. Patenting BiosimilarsClaudia Mund 2. Patenting DiagnosticsDieter Wächter 3. Patenting Human Genes in Europe- And how it compares to the US and AustraliaTimo Minssen4. Patenting Human Genes in the United StatesSamantak Gosh5. An Exorbitant Monopoly: The High Court of Australia, Myriad Genetics, and Gene PatentsMatthew Rimmer6. Exclusivity for BiologicsDuncan Matthews Part II - Agricultural Sector (Crop Sciences)7. Protection of Plant InnovationsGert Würtenberger8. Patenting Non Transgenic Plants in the EUMichael A. Kock9. Non-Obvious PlantsMark D. Janis 10. Transgenic PlantsJames Allred11. Convention on Biological Diversity and Regulatory Law as Plant ProtectionClaudio Chiarolla 12. Patents on Native Traits: What Scope of Protection?Axel Metzger Part III - Research and Development13. The European Union’s IP Policy and Funding of Stem Cell Research Aurora Plomer 14. Stem Cell Patents in the United StatesJohn M. Golden 15. Early Stage Patenting, the US Bayh-Dole Act, and the Anti-Commons HypothesisCharles R. McManis and Brian Yagi16. IP in Research and Development AgreementsMelanie Graf and Herbert Zech 17. Patent pools and clearinghouses in the life sciences: back to the futureGeertrui Van OverwallePart IV - Country Case Studies in IP and the Life Sciences18. Understanding the Brazilian Patent ReformPedro Paranaguá19. IP protection in the life sciences in ChinaLin Xiuqin and Zhang Xinfeng20. Diverse Harmonization: Indian ExampleSrividhya Ragavan 21. Life Science Research and Patents in Japan: A Comparative Study of Life Science Invention Patentability between the Japanese and US Patent ActsToshiko Takenaka 22. Intellectual Property and the Life Sciences in Kenya: Enforcement and Access to MedicinesJohn Harrington 23. IP and Life Sciences: A Case Study of South AfricaTenu Avafia 24. Thailand’s Compulsory Licenses and the Increase of Investment ArbitrationDavid B. DegenPart V - Boundaries of IP and the Life Sciences25. Parallel Imports within the European UnionGert Würtenberger26. Pay for Delay AgreementsClaudia Seitz 27. Abusive Filing of IP RightsAndreas HeinemannIndex

'This exciting volume offers fresh perspectives on the role of IP in areas of high importance, including traditional pharmaceutical industries, biologic drugs and biotechnology, and agriculture. The book also features analyses of IP in national and regional approaches to research and development, and fresh case studies of country experiences. With the participation of authors from a wide range of countries, the volume provides new insights on the law and politics of IP in the life sciences with a truly global perspective. This book will serve as a valuable reference for scholars, students, and practioners.'

Edited by Duncan Matthews, Professor of Intellectual Property Law, Queen Mary University of London, UK and Herbert Zech, Humboldt University, Berlin, Germany

• Contents:PrefacePart I - Medicine and Pharmaceutics1. Patenting BiosimilarsClaudia Mund 2. Patenting DiagnosticsDieter Wächter 3. Patenting Human Genes in Europe- And how it compares to the US and AustraliaTimo Minssen4. Patenting Human Genes in the United StatesSamantak Gosh5. An Exorbitant Monopoly: The High Court of Australia, Myriad Genetics, and Gene PatentsMatthew Rimmer6. Exclusivity for BiologicsDuncan Matthews Part II - Agricultural Sector (Crop Sciences)7. Protection of Plant InnovationsGert Würtenberger8. Patenting Non Transgenic Plants in the EUMichael A. Kock9. Non-Obvious PlantsMark D. Janis 10. Transgenic PlantsJames Allred11. Convention on Biological Diversity and Regulatory Law as Plant ProtectionClaudio Chiarolla 12. Patents on Native Traits: What Scope of Protection?Axel Metzger Part III - Research and Development13. The European Union’s IP Policy and Funding of Stem Cell Research Aurora Plomer 14. Stem Cell Patents in the United StatesJohn M. Golden 15. Early Stage Patenting, the US Bayh-Dole Act, and the Anti-Commons HypothesisCharles R. McManis and Brian Yagi16. IP in Research and Development AgreementsMelanie Graf and Herbert Zech 17. Patent pools and clearinghouses in the life sciences: back to the futureGeertrui Van OverwallePart IV - Country Case Studies in IP and the Life Sciences18. Understanding the Brazilian Patent ReformPedro Paranaguá19. IP protection in the life sciences in ChinaLin Xiuqin and Zhang Xinfeng20. Diverse Harmonization: Indian ExampleSrividhya Ragavan 21. Life Science Research and Patents in Japan: A Comparative Study of Life Science Invention Patentability between the Japanese and US Patent ActsToshiko Takenaka 22. Intellectual Property and the Life Sciences in Kenya: Enforcement and Access to MedicinesJohn Harrington 23. IP and Life Sciences: A Case Study of South AfricaTenu Avafia 24. Thailand’s Compulsory Licenses and the Increase of Investment ArbitrationDavid B. DegenPart V - Boundaries of IP and the Life Sciences25. Parallel Imports within the European UnionGert Würtenberger26. Pay for Delay AgreementsClaudia Seitz 27. Abusive Filing of IP RightsAndreas HeinemannIndex

'This exciting volume offers fresh perspectives on the role of IP in areas of high importance, including traditional pharmaceutical industries, biologic drugs and biotechnology, and agriculture. The book also features analyses of IP in national and regional approaches to research and development, and fresh case studies of country experiences. With the participation of authors from a wide range of countries, the volume provides new insights on the law and politics of IP in the life sciences with a truly global perspective. This book will serve as a valuable reference for scholars, students, and practioners.'